WuXi’s subsidiary (STA) opens facility in San Diego

WuXi AppTec, a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary, Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA), is opening operations in San Diego, which provides Process R&D and API manufacturing services for early phase clinical studies.

CEO of STA, Dr. Minzhang Chen, commented, “STA is a leading global Contract Development and Manufacturing Organization for innovative small molecule active pharmaceutical ingredients and advanced intermediates, from preclinical through commercial. Our new U.S. based presence with a highly experienced scientific and production team is another step towards better enabling our partners through added capacity, greater flexibility, and our customer-centric approach to drug development and manufacturing services.”

Chairman and CEO of WuXi AppTec, Dr. Ge Li, added, “WuXi’s open-access capability and technology platform strives to enable anyone and any company to discover and develop healthcare products more efficiently and cost effectively. This new facility further brings our comprehensive R&D services closer to our North American customers and partners in their efforts to improve patients’ lives.”

WuXi also has U.S. facilities in Cambridge, Plainsboro, Philadelphia, Lansdale, St. Paul, Atlanta, and global presence in Germany, Iceland, Israel, South Korea, and Japan. Headquartered in Shanghai, WuXi has a global footprint of over 6.0 million square feet of R&D space across 26 sites around the world.

Press release from http://www.wuxiapptec.com

---

---

Related Topics and Keywords

Ltd, San Diego, Shanghai SynTheAll Pharmaceutical Co, STA, WuXi